Get the Stockscreener App
76.51
1.24%
0.94
After Hours:
76.63
0.12
+0.16%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $76.51, with a volume of 6.19M.
It is up +1.24% in the last 24 hours and up +2.77% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$75.57
Open:
$76.7
24h Volume:
6.19M
Relative Volume:
1.18
Market Cap:
$237.21B
Revenue:
$54.07B
Net Income/Loss:
$7.04B
P/E Ratio:
33.93
EPS:
2.255
Net Cash Flow:
$7.28B
1W Performance:
-1.24%
1M Performance:
+2.77%
6M Performance:
-2.25%
1Y Performance:
+13.21%
1-Day Range:
$76.17
$77.03
1-Week Range:
$74.18
$78.25
52-Week Range:
$62.75
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
76.51 | 237.21B | 54.07B | 7.04B | 7.28B | 2.255 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Antiplatelet Drugs Market Is Booming Worldwide 2025-2032 | AstraZeneca Plc, Daiichi Sankyo, Inc., Sanofi - openPR
Del. Justices Told Conflicts Tainted AstraZeneca Co.'s $3B Sale - Law360
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Delaware High Court Weighs Reviving AstraZeneca Shareholder Suit - Bloomberg Law
Capital Group Increases Stake in AstraZeneca - TipRanks
AstraZeneca experimental blood pressure drug has a good shot of becoming a blockbuster - Proactive Investors UK
Dermatomyositis Treatment Market Size Report 2034 | - openPR
AstraZeneca PLC (NASDAQ:AZN) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securitie - GuruFocus.com
AstraZeneca's $1B Drug Protections Too Vague, Generics Say - Law360
Mineralys' drug for persistent hypertension succeeds in two trials -March 10, 2025 at 11:02 am EDT - Marketscreener.com
FTSE 100 Live: Stocks slide at open, AstraZeneca and Reckitt lead fallers - Proactive Investors Australia
Global Prostate Cancer Market to Reach USD 29.2 Billion by 2035, Driven by Aging Population and Awareness | Future Market Insights, Inc. - GlobeNewswire Inc.
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Shore Capital Reaffirms “Buy” Rating for AstraZeneca (LON:AZN) - Defense World
AstraZeneca Pharma India secures CDSCO nod to import, sell Durvalumab for small cell lung cancer - Medical Dialogues
AstraZeneca PLC's (LON:AZN) Intrinsic Value Is Potentially 81% Above Its Share Price - Simply Wall St
AstraZeneca CEO acquires shares after performance plan vests - Investing.com India
Gastric Cancer Is Another Perioperative Win For AstraZeneca’s Imfinzi - Citeline News & Insights
AstraZeneca’s Imfinzi shows promise in gastric cancer trial By Investing.com - Investing.com South Africa
AstraZeneca’s Imfinzi shows promise in gastric cancer trial - Investing.com India
Astrazeneca Adjunctive Gastric Cancer Treatment Study Meets Primary Endpoint -March 07, 2025 at 07:56 am EST - Marketscreener.com
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients - Yahoo Finance
AstraZeneca sets AGM for April 11, outlines agenda - Investing.com
AstraZeneca schedules digital AGM for April 11, 2025 - Investing.com
Form 6-K ASTRAZENECA PLC For: Mar 07 - StreetInsider.com
SEC Form 6-K filed by AstraZeneca PLC - Quantisnow
AstraZeneca’s Imfinzi success a step towards $80bn revenue aimanalyst - Proactive Investors UK
AstraZeneca Releases Imfinzi Update March 7, 2025 - James Sharp & Co.
AstraZeneca: promising results in gastric cancer -March 07, 2025 at 04:44 am EST - Marketscreener.com
AstraZeneca's Imfinzi Shows Positive Results in Late-stage Gastric Cancer Trial -March 07, 2025 at 03:09 am EST - Marketscreener.com
AstraZeneca Plc Imfinzi demonstrates improved EFS in early stage gastric cancer - DirectorsTalk Interviews
AstraZeneca's Imfinzi shows promise in early-stage stomach and oesophageal cancer - Proactive Investors UK
AstraZeneca revenue by therapeutic area 2022-2024 - Statista
AstraZeneca hails trial results for imfinzi on gastric cancer - ShareCast
Astrazeneca Says Imfinzi Improved EFS In Early-Stage Gastric Cancer -March 07, 2025 at 02:10 am EST - Marketscreener.com
CDSCO nod to AstraZeneca to import, sell hyperkalaemia treatment drug in India - Medical Dialogues
AstraZeneca executives acquire shares post bonus deferral - Investing.com India
Liverpool Lib Dems say 'we want answers' over AstraZeneca deal - Liverpool Echo
AstraZeneca revenue from Crestor 2006-2024 - Statista
Is AstraZeneca PLC (LON:AZN) Trading At A 45% Discount? - Yahoo Finance
AstraZeneca Executives Receive Share Awards Under Bonus Plans - Investing.com
AstraZeneca Awards Shares to CEO and CFO Under Incentive Plans - TipRanks
AstraZeneca: A Big Pharma Blue Chip To Buy Now (NASDAQ:AZN) - Seeking Alpha
Class Action Filed Against AstraZeneca PLC (AZN) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Rhumbline Advisers Has $1.91 Million Position in AstraZeneca PLC (NASDAQ:AZN) - Defense World
AstraZeneca And GSK Put Spotlight On Nasal Polyps Space - Insights
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis - Benzinga
AstraZeneca reports total voting rights as of February end By Investing.com - Investing.com Australia
AstraZeneca reports total voting rights as of February end - Investing.com
AstraZeneca Announces Share Capital and Voting Rights Update - TipRanks
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):